Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case Report-Reference-Cited by-同舟云学术

Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case Report

Published:2023 Issue: Volume: Page:
ISSN:1881-641X
Container-title:Annals of Vascular Diseases
language:en
Short-container-title:Annals of Vascular Diseases

Author:

Nomura Takuo¹,Hata Akito²

Affiliation:

1. Department of Vascular Surgery, Juzen Memorial Hospital, Hamamatsu, Shizuoka, Japan

2. Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan

Publisher

The Editorial Committee of Annals of Vascular Diseases

Subject

Pharmaceutical Science

Link

https://www.jstage.jst.go.jp/article/avd/advpub/0/advpub_cr.23-00059/_pdf

Reference10 articles.

1. 1) Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019; 69 Suppl: 3S–125S, e40.

2. 2) Iida O, Takahara M, Soga Y, et al. Three-year outcomes of surgical versus endovascular revascularization for critical limb ischemia: The SPINACH Study (Surgical Reconstruction Versus Peripheral Intervention in Patients With Critical Limb Ischemia). Circ Cardiovasc Interv 2017; 10: e005531.

3. 3) Mirault T, Rea D, Azarine A, et al. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. Eur J Haematol 2015; 94: 363–7.

4. 4) Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma 2016; 57: 1300–10.

5. 5) Talpaz M, Cortes JE, Kantarjian HM, et al. Longer-term follow up of a phase 1 study of ponatinib in patient (pts) with Philadelphia chromosome-positive (Ph+) leukemias. J Clin Oncol 2014; 32 suppl: 7078.